Synthetic heterocyclic candidates as promising α-glucosidase inhibitors: An overview

α-Glucosidase enzyme inhibition is an effective therapeutic decorum in the treatment of type 2 diabetes mellitus. Since 1990, three α-glucosidase inhibitors are known to exist clinically, Acarbose, Voglibose and Miglitol. Side effects and long synthetic routes to access them forced the researchers t...

Full description

Saved in:
Bibliographic Details
Published in:European journal of medicinal chemistry 2019-08, Vol.176, p.343-377
Main Authors: Dhameja, Manoj, Gupta, Preeti
Format: Article
Language:English
Subjects:
Docking study
Heterocyclic compounds
Structure activity relationship (SAR)
α-Glucosidase inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:α-Glucosidase enzyme inhibition is an effective therapeutic decorum in the treatment of type 2 diabetes mellitus. Since 1990, three α-glucosidase inhibitors are known to exist clinically, Acarbose, Voglibose and Miglitol. Side effects and long synthetic routes to access them forced the researchers to move their focus to discover simple and small heterocyclic motifs that work as promising α-glucosidase inhibitors and may eventually lead to the management of postprandial hyperglycemic condition in T2DM. In this regards, this review deals with recently discovered heterocyclic molecules that have been evaluated to exhibit inhibition of α-glucosidase enzyme. [Display omitted] •Recently designed and developed heterocyclic α-glucosidase inhibitors.•All synthetic heterocyclic derivatives and hybrids covered till 2018 literature.•Structural activity relationship (SAR) of heterocyclic α-glucosidase inhibitors included.•Binding interactions of most active inhibitors discussed.
ISSN:0223-5234
1768-3254
DOI:10.1016/j.ejmech.2019.04.025